dc.creatorDuncan, Christopher J.A.
dc.creatorRandall, Richard E.
dc.creatorHambleton, Sophie
dc.date.accessioned2020-09-25T20:38:12Z
dc.date.accessioned2022-09-23T18:05:59Z
dc.date.available2020-09-25T20:38:12Z
dc.date.available2022-09-23T18:05:59Z
dc.date.created2020-09-25T20:38:12Z
dc.identifier1362-4555
dc.identifierhttps://doi.org/10.1016/j.tig.2020.08.017
dc.identifierhttp://hdl.handle.net/20.500.12010/13831
dc.identifierhttps://doi.org/10.1016/j.tig.2020.08.017
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3495157
dc.description.abstractThe concept that type I interferons (IFN-I) are essential to antiviral immunity derives from studies on animal models and cell lines. Virtually all pathogenic viruses have evolved countermeasures to IFN-I restriction, and genetic loss of viral IFN-I antagonists leads to virus attenuation. But just how important is IFN-I to antiviral defence in humans? The recent discovery of genetic defects of IFN-I signalling illuminates this and other questions of IFN biology, including the role of the mucosa-restricted type III IFNs (IFN-III), informing our understanding of the place of the IFN system within the concerted antiviral response. Here we review monogenic lesions of IFN-I signalling pathways and summarise the organising principles which emerge.
dc.languageeng
dc.publisherTrends in genetics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectHuman antiviral immunity
dc.subjectGenetic lesions
dc.titleGenetic lesions of type i interferon signalling in human antiviral immunity


Este ítem pertenece a la siguiente institución